<DOC>
	<DOCNO>NCT01193283</DOCNO>
	<brief_summary>Background : - Severe aplastic anemia ( SAA ) lead problem bone marrow health result low blood cell count , require frequent transfusion . Standard treatment SAA involve injection antithymocyte globulin ( ATG ) plus cyclosporine ( CsA ) . This regimen show improve blood count two-thirds patient . However , ATG/CsA regimen follow limitation : ( ) disease come back ( relapse ) one-third patient improve initially ; ( b ) 10 % 15 % case , certain type bone marrow cancer ( myelodysplasia leukemia ) develop ( call evolution ) . Experience drug SAA cyclophosphamide suggest similar response rate ATG/CsA achieve low risk relapse clonal evolution . However , cyclophosphamide find significant side effect SAA investigate 10 year ago due increase risk fungal infection . - Better antibiotic drug fungus develop widely use treat patient low white blood cell count risk develop infection . In SAA patient particular , new antibiotic large impact prevent treat fungus infection . Researchers revisit use cyclophosphamide SAA treatment , plan give low dose CsA combination immune-suppressing drug cyclophosphamide , well antibiotic protect infection , possible treatment disease . Objectives : - To determine safety effectiveness combination cyclophosphamide cyclosporine treat severe aplastic anemia treat immunosuppressive therapy .</brief_summary>
	<brief_title>Cyclophosphamide Plus Cyclosporine Treatment-Naive Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic hematopoietic stem cell transplantation ( HSCT ) offer opportunity cure 70 percent patient , patient suitable candidate treatment modality due advanced age , comorbidities lack histocompatible donor . For patient , comparable long-term survival attainable immunosuppressive treatment ( IST ) anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) . However , approximately 1/3 patient show blood count improvement ATG/CsA consider refractory disease . Furthermore , analysis extensive clinical data suggest poor blood count response single course ATG ( non-robust responder ) , even transfusion-independence achieve , predicts markedly bad prognosis compare achieve robust hematologic improvement ( protocol 90-H-0146 ) . The current limitation IST SAA : 1 ) majority responses observe follow initial h-ATG/CsA partial patient achieve normal blood count ; 2 ) 1/3 patient refractory initial h-ATG/CsA ; 3 ) hematologic relapse occur 35 percent responder follow initial response h-ATG/CsA ; 4 ) among relapsed patient chronic use CsA infrequent often lead toxicity long term exposure drug ( especially old patient ) ; 5 ) clonal evolution still observe 10-15 percent patient . Efforts improve initial IST treatment-naive patient addition mycophenolate mofetil sirolimus standard h-ATG/CsA use lymphocytotoxic agent r-ATG/CsA alemtuzumab yield expect well outcomes compare standard h-ATG/CsA ( protocols 00-H-0032 , 03-H-0193 , 06-H-0034 ) . Because majority SAA patient US worldwide treat IST due lack human leukocyte antigen ( HLA ) -matched donor inaccessibility transplant , novel regimen need overcome current limitation IST SAA . Towards goal address limitation propose regimen cyclophosphamide ( Cy ) plus low dose CsA . Cy propose investigator Johns Hopkins alternative IST regimen h-ATG/CsA . In pilot study , high dose Cy ( 200 mg/kg ) yield similar result observe h-ATG/CsA . In randomized study , National Institute Heart , Lung , BIood ( NHLBI ) , compare high dose Cy ( 200 mg/kg ) h-ATG/CsA treatment-na ( SqrRoot ) patient ( protocol 97-H-0117 ) , excess toxicity death invasive fungal infection observe Cy arm lead discontinuation regimen . Recently report long-term result Johns Hopkins 44 treatment-naive patient receive high dose Cy ( 200 mg/kg ) sole therapy SAA show great number complete response observe instance relapse clonal evolution note Cy compare h-ATG/CsA ( historical comparison ) . In accompany editorial , incidence invasive fungal infection cohort highlight . Of note , antifungal prophylaxis Aspergillus sp , deadly culprit neutropenia severe prolong , employed Hopkins high dose Cy protocol . In Chinese experience , data present recent meeting Japan show low dos Cy ( 120 mg/kg ) plus CsA achieve similar result report Hopkins investigator reduce toxicity . These data suggest Cy activity SAA could viable alternative standard h-ATG/CsA immediate toxicity associate prolonged neutropenia could overcome . In recent year observe marked improvement survival SAA patient especially among non-responders IST pancytopenia remain persistent month . A detailed analysis ( show Section 2.4 Scientific Clinical Justification Protocol ) show good antifungal supportive care recent year contribute reduction infection-related mortality month follow IST among non-responders , remain persistently neutropenic . This observation suggest nowadays patient well support period neutropenia due improve antifungal supportive care agent well tolerate ( compare deoxycholate amphotericin B ) , retain broad-spectrum activity ( especially Aspergillus sp ) , administer orally outpatient . The fact one-third initial refractory patient respond retreatment late complication ( relapse clonal evolution ) occur 40-50 percent case suggest initial IST h-ATG/CsA important limitation . Therefore , propose investigate Cy + CsA initial therapy SAA . Our intention recapitulate high dose Cy regimen initially propose Hopkins ( 200 mg/kg ) instead , investigate low dos propose Chinese ( 120 mg/kg ) addition low dose CsA ( target therapeutic level 100 200 microg/L ) . The ability well support patient period neutropenia well antifungal allow immediate toxicity overcome ass activity Cy SAA . The main objective study assess safety efficacy Cy 120 mg/kg + low dose CsA ( 100 200 microg/L ) treatment-naive SAA . The primary endpoint hematologic response , define longer meet criterion SAA , 6 month . Secondary endpoint relapse , robustness hematologic recovery 6 month , response 3 month 12 month , survival , clonal evolution paroxysmal nocturnal hemoglobinuria ( PNH ) , myelodysplasia acute leukemia . The primary endpoint change absolute neutrophil count , platelet count , reticulocyte count 6 month . Secondary endpoint include time relapse , change cytogenetics , time death .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : Severe aplastic anemia characterize : Bone marrow cellularity le 30 percent ( exclude lymphocyte ) AND At least two follow : Absolute neutrophil count le 500/ microL Platelet count le 20,000/ microL Absolute reticulocyte count le 60,000/ microL Age great equal 2 year old Weight great equal 12 kg EXCLUSION CRITERIA : Diagnosis Fanconi anemia Cardiac ejection fraction le 30 percent ( evaluated ECHO ) Evidence clonal hematologic bone marrow disorder cytogenetics . Patients presence trisomy 8 , loss Y del ( 20q ) exclude absence dysplastic change marrow . Patients severe neutropenia ( ANC less 200 /microL ) exclude initially cytogenetics available pending . If evidence clonal disorder later identify , patient go study . Prior immunosuppressive therapy high dose Cy ATG Infection adequately control appropriate therapy Serologic evidence HIV infection Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient ability tolerate protocol therapy , death within 30 day likely Subjects cancer consider cure , active chemotherapeutic treatment take drug hematological effect Current pregnancy unwillingness take oral contraceptive refrain pregnancy childbearing potential Not able understand investigational nature study give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Aplastic Anemia</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>T-Cells</keyword>
	<keyword>Hematopoiesis</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
</DOC>